KCT0009186已完成Unknown
A 24-Week, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of Proso Millet and Wheat Extract(Keranat™) on Hair Health
ovarex0 个研究点目标入组 100 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19(Year) 至 60(Year)（—）
- 性别
- All
入选标准
- •1) Age 19 and 60
- •2) Hair gloss score of 3 or less and a hair damage score of less than 18 according to the visual evaluation classification method.
- •3) Willing to maintain the same hairstyle, hair color, hair length, and hair regimen throughout the study period.
- •4) Subject must be able to comprehend and voluntarily sign study procedures
- •and consent forms.
排除标准
- •1) Those diagnosed with and receiving treatment for the alopecia within 3months before screening(androgenetic alopecia, alopecia areata, Telogen effluvium, etc.)
- •2) Use of that may affect hair or hair loss symptoms treatment medicine, dietary supplements, or treatments containing herbal medicine ingredients within 3 months before screening.
- •3) Any active scalp or skin disease that may interfere with the study treatment and evaluations.
- •4) Pregnancy or breastfeeding or planning pregnancy
- •5) Case of abnormal values at creatinine (excess at the upper limit of the reference range)
- •6) Case of abnormal values at ALT or AST (2 times excess at the upper limit of the reference range)
研究者
相似试验
已完成
2 期
Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label OfatumumabRelapsing Multiple SclerosisJPRN-jRCT2080223655ovartis Pharma K.K.30
进行中（未招募）
不适用
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease. - N/AChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 13.1Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-023349-32-GRGlaxoSmithKline Research & Development Ltd1,463
进行中（未招募）
不适用
A Study to Evaluate the Safety and Efficacy of Three Different Medicines to Treat COPDChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 13.1Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-023348-33-SEGlaxoSmithKline Research & Development Ltd1,463
进行中（未招募）
不适用
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease. - N/AChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.1Level: LLTClassification code 10009033Term: Chronic obstructive pulmonary diseaseEUCTR2010-023348-33-HUGlaxoSmithKline Research & Development Ltd1,463
进行中（未招募）
不适用
A Study to Evaluate the Safety and Efficacy of Three Different Medicines to Treat COPDChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 14.0Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-023348-33-DKGlaxoSmithKline Research & Development Ltd1,463